Novabay Pharmaceuticals Stock EBITDA

NBY Stock

USD 0.68 0.04 5.56%

NovaBay Pharmaceuticals fundamentals help investors to digest information that contributes to NovaBay Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NovaBay Stock. The fundamental analysis module provides a way to measure NovaBay Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NovaBay Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	-4.8 M	-5 M

EBITDA is likely to drop to about (5 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NovaBay Pharmaceuticals Company EBITDA Analysis

NovaBay Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current NovaBay Pharmaceuticals EBITDA

(4.8 M)

Most of NovaBay Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NovaBay Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

NovaBay EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for NovaBay Pharmaceuticals is extremely important. It helps to project a fair market value of NovaBay Stock properly, considering its historical fundamentals such as EBITDA. Since NovaBay Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NovaBay Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NovaBay Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Total Liab	Net Debt	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	0.45	-0.61	-0.25	-0.16	0.87	0.59	0.3	-0.11	0.0	-0.28	0.17	0.24	-0.17	-0.4	0.09	0.45	0.47	0.25
Total Stockholder Equity	0.83		-0.11	-0.76	-0.04	-0.4	0.88	0.62	0.33	0.06	-0.18	-0.12	0.58	0.1	-0.34	-0.42	0.19	0.5	0.51	0.23
Total Liab	0.45	-0.11		0.06	-0.34	0.37	0.16	0.1	-0.06	-0.29	0.24	-0.29	-0.6	0.25	0.24	-0.02	-0.14	0.04	0.06	0.04
Net Debt	-0.61	-0.76	0.06		-0.39	0.22	-0.86	-0.49	0.19	0.16	0.17	0.21	-0.69	0.3	0.22	0.15	-0.55	-0.29	-0.4	0.35
Retained Earnings	-0.25	-0.04	-0.34	-0.39		-0.06	0.06	-0.08	-0.42	0.05	-0.13	0.05	0.51	-0.94	-0.08	0.31	0.44	-0.42	-0.27	-0.65
Accounts Payable	-0.16	-0.4	0.37	0.22	-0.06		-0.29	0.14	0.09	-0.65	0.23	-0.48	-0.69	0.0	0.05	-0.16	0.12	-0.17	-0.13	0.11
Total Current Assets	0.87	0.88	0.16	-0.86	0.06	-0.29		0.51	0.15	-0.1	-0.02	-0.28	0.51	-0.04	-0.17	-0.17	0.27	0.28	0.32	-0.04
Common Stock	0.59	0.62	0.1	-0.49	-0.08	0.14	0.51		0.19	-0.28	0.05	-0.28	0.06	0.16	-0.61	-0.39	0.12	0.53	0.54	0.37
Property Plant Equipment	0.3	0.33	-0.06	0.19	-0.42	0.09	0.15	0.19		-0.08	0.26	-0.36	-0.19	0.35	-0.08	-0.42	-0.14	-0.02	-0.1	0.79
Current Deferred Revenue	-0.11	0.06	-0.29	0.16	0.05	-0.65	-0.1	-0.28	-0.08		-0.69	0.88	0.28	0.01	0.13	0.39	-0.56	-0.06	-0.06	0.05
Short Term Debt	0.0	-0.18	0.24	0.17	-0.13	0.23	-0.02	0.05	0.26	-0.69		-0.74	-0.28	0.01	-0.17	-0.04	0.19	-0.27	-0.35	0.08
Net Receivables	-0.28	-0.12	-0.29	0.21	0.05	-0.48	-0.28	-0.28	-0.36	0.88	-0.74		0.15	0.06	0.08	0.38	-0.53	0.06	0.05	-0.06
Net Tangible Assets	0.17	0.58	-0.6	-0.69	0.51	-0.69	0.51	0.06	-0.19	0.28	-0.28	0.15		-0.41	-0.13	0.01	0.4	0.14	0.2	-0.39
Capital Surpluse	0.24	0.1	0.25	0.3	-0.94	0.0	-0.04	0.16	0.35	0.01	0.01	0.06	-0.41		0.02	-0.35	-0.43	0.52	0.39	0.67
Deferred Long Term Liab	-0.17	-0.34	0.24	0.22	-0.08	0.05	-0.17	-0.61	-0.08	0.13	-0.17	0.08	-0.13	0.02		0.18	0.12	-0.14	-0.13	-0.07
Short Long Term Debt	-0.4	-0.42	-0.02	0.15	0.31	-0.16	-0.17	-0.39	-0.42	0.39	-0.04	0.38	0.01	-0.35	0.18		-0.39	-0.66	-0.67	-0.43
Cash And Equivalents	0.09	0.19	-0.14	-0.55	0.44	0.12	0.27	0.12	-0.14	-0.56	0.19	-0.53	0.4	-0.43	0.12	-0.39		0.11	0.22	-0.34
Net Invested Capital	0.45	0.5	0.04	-0.29	-0.42	-0.17	0.28	0.53	-0.02	-0.06	-0.27	0.06	0.14	0.52	-0.14	-0.66	0.11		0.98	0.3
Net Working Capital	0.47	0.51	0.06	-0.4	-0.27	-0.13	0.32	0.54	-0.1	-0.06	-0.35	0.05	0.2	0.39	-0.13	-0.67	0.22	0.98		0.19
Capital Stock	0.25	0.23	0.04	0.35	-0.65	0.11	-0.04	0.37	0.79	0.05	0.08	-0.06	-0.39	0.67	-0.07	-0.43	-0.34	0.3	0.19

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict NovaBay Pharmaceuticals

Ebitda Over Time

NovaBay Ebitda

Ebitda

(5.04 Million)

NovaBay Pharmaceuticals reported EBITDA of (4.8 Million) in 2023

According to the company disclosure, NovaBay Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (4.8 Million). This is 100.55% lower than that of the Pharmaceuticals sector and 104.79% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.12% higher than that of the company.

NovaBay EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NovaBay Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NovaBay Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NovaBay Pharmaceuticals by comparing valuation metrics of similar companies.

NovaBay Pharmaceuticals is currently under evaluation in ebitda category among its peers.

NovaBay Fundamentals

	Return On Equity	-2.64
	Return On Asset	-0.39
	Profit Margin	(0.77) %
	Operating Margin	(0.43) %
	Current Valuation	3.82 M
	Shares Outstanding	4.89 M
	Shares Owned By Insiders	0.02 %
	Shares Owned By Institutions	2.58 %
	Number Of Shares Shorted	764.28 K
	Price To Earning	(5.43) X
	Price To Book	3.12 X
	Price To Sales	0.25 X
	Revenue	14.73 M
	Gross Profit	5.64 M
	EBITDA	(4.8 M)
	Net Income	(9.64 M)
	Cash And Equivalents	5.36 M
	Cash Per Share	0.07 X
	Total Debt	2.74 M
	Debt To Equity	0.14 %
	Current Ratio	2.59 X
	Book Value Per Share	0.22 X
	Cash Flow From Operations	(4.13 M)
	Short Ratio	0.83 X
	Earnings Per Share	(74.61) X
	Target Price	3.73
	Number Of Employees	24
	Beta	0.73
	Market Capitalization	3.33 M
	Total Asset	9.03 M
	Retained Earnings	(174.85 M)
	Working Capital	2.88 M
	Current Asset	4.53 M
	Current Liabilities	4.63 M
	Net Asset	9.03 M

About NovaBay Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NovaBay Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NovaBay Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NovaBay Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC